Patents by Inventor Michel L. TREMBLAY

Michel L. TREMBLAY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10150787
    Abstract: The invention encompasses the novel class of compounds represented by the Formula (I) below, which are inhibitors of the TC-PTP enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing TC-PTP mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the immunotherapeutic treatment of diseases.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: December 11, 2018
    Inventors: Michel L. Tremblay, Claudia Penafuerte, Matthew Feldhammer, George Zogopoulos, Cameron Black, Brian Kennedy
  • Publication number: 20180265531
    Abstract: The invention encompasses the novel class of compounds represented by the Formula (I) below, which are inhibitors of the TC-PTP enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing TC-PTP mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the immunotherapeutic treatment of diseases.
    Type: Application
    Filed: May 22, 2018
    Publication date: September 20, 2018
    Inventors: Michel L. TREMBLAY, Claudia PENAFUERTE, Matthew FELDHAMMER, George ZOGOPOULOS, Cameron BLACK, Brian KENNEDY
  • Patent number: 10005804
    Abstract: The invention encompasses the novel class of compounds represented by the Formula (I) below, which are inhibitors of the TC-PTP enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing TC-PTP mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the immunotherapeutic treatment of diseases.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: June 26, 2018
    Inventors: Michel L. Tremblay, Claudia Penafuerte, Matthew Feldhammer, George Zogopoulos, Cameron Black, Brian Kennedy
  • Publication number: 20180072763
    Abstract: The invention encompasses the novel class of compounds represented by the Formula (I) below, which are inhibitors of the TC-PTP enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing TC-PTP mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the immunotherapeutic treatment of diseases.
    Type: Application
    Filed: September 20, 2017
    Publication date: March 15, 2018
    Inventors: Michel L. TREMBLAY, Claudia PENAFUERTE, Matthew FELDHAMMER, George ZOGOPOULOS, Cameron BLACK, Brian KENNEDY
  • Patent number: 9828399
    Abstract: The invention encompasses the novel class of compounds represented by the Formula (I) below, which are inhibitors of the TC-PTP enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing TC-PTP mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the immunotherapeutic treatment of diseases.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: November 28, 2017
    Assignee: The Royal Institution For The Advancement Of Learning/McGill University
    Inventors: Michel L. Tremblay, Claudia Penafuerte, Matthew Feldhammer, George Zogopoulos, Cameron Black, Brian Kennedy
  • Publication number: 20170015690
    Abstract: The invention encompasses the novel class of compounds represented by the Formula (I) below, which are inhibitors of the TC-PTP enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing TC-PTP mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the immunotherapeutic treatment of diseases.
    Type: Application
    Filed: February 27, 2015
    Publication date: January 19, 2017
    Applicant: THE ROYAL INSTITUTE FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY
    Inventors: Michel L. TREMBLAY, Claudia PENAFUERTE, Matthew FELDHAMMER, George ZOGOPOULOS, Cameron BLACK, Brian KENNEDY